scholarly journals Tumor cells may circulate in medullary thyroid cancer patients independently of serum calcitonin

2018 ◽  
Vol 25 (12) ◽  
pp. L59-L63 ◽  
Author(s):  
Sathya Neelature Sriramareddy ◽  
Etienne Hamoir ◽  
Marcela Chavez ◽  
Renaud Louis ◽  
Albert Beckers ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Medullary Thyroid Cancer ◽  
Serum Calcitonin ◽  
Medullary Thyroid

CALCITONIN HETEROGENEITY IN LUNG CANCER AND MEDULLARY THYROID CANCER

1978 ◽  
Vol 89 (1) ◽  
pp. 89-99 ◽  
Author(s):  
Kenneth L. Becker ◽  
Richard H. Snider ◽  
Omega L. Silva ◽  
Charles F. Moore
Keyword(s):  
Thyroid Cancer ◽  
Cancer Patients ◽  
Medullary Thyroid Cancer ◽  
Gel Filtration ◽  
Serum Calcitonin ◽  
Medullary Thyroid ◽  
Fraction I ◽  
Bronchogenic Cancer

ABSTRACT An investigation was made of the increased serum calcitonin in patients with medullary thyroid cancer and bronchogenic carcinoma in order to determine whether these conditions can be differentiated immunochemically. Endogenous fractions of immunoreactive calcitonin were separated by gel filtration and radioimmunoassayed with calcitonin antibodies having different region specificities. The pattern of serum heterogeneity of patients with medullary thyroid cancer was characterized by the presence of at least seven different fractions of immunoreactive calcitonin, ranging from fraction I (≧ 30 000 molecular weight (MW)) to fraction V (~ 2500 MW). In contrast, most patients with bronchogenic cancer had a predominance of high MW fractions (i. e. fractions I and II A). Following in vitro incubation of the serum, the typical large MW pattern of bronchogenic cancer serum could be converted to the more diffuse pattern seen in the serum of medullary thyroid cancer. We were able to differentiate, pre-operatively, the hypercalcitonaemia serum of medullary thyroid cancer patients from that of bronchogenic cancer patients by determination of the ratio of calcitonin as radioimmunoassayed with midportion versus carboxyl terminal antibody.

scholarly journals Surgical approach to medullary thyroid cancer

2007 ◽  
Vol 51 (5) ◽  
pp. 818-824 ◽  
Author(s):  
Catharina Ihre Lundgren ◽  
Leigh Delbridg ◽  
Diana Learoyd ◽  
Bruce Robinson
Keyword(s):  
Thyroid Cancer ◽  
Total Thyroidectomy ◽  
Medullary Thyroid Cancer ◽  
Prophylactic Surgery ◽  
Surgical Removal ◽  
Serum Calcitonin ◽  
Medullary Thyroid ◽  
Central Lymph Node Dissection ◽  
Familial Form ◽  
Men 2A

Medullary thyroid cancer (MTC) compromises 3-5% of all thyroid cancers and arises from parafollicular or calcitonin-producing C cells. It may be sporadic (75% of cases), or may occur as a manifestation of either the hereditary syndrome Multiple Endocrine Neoplasia type 2 (MEN 2A or MEN 2B) (25% of cases), or rarely as an isolated familial syndrome (FMTC). Complete surgical resection comprising in most cases total thyroidectomy with central lymph node dissection at an early stage of the disease is the only potential cure for MTC. The familial form of the disease, MEN-2A occupies a unique place in surgical history, having been the first disease where surgical removal of an affected organ was undertaken before the development of malignancy, solely on the basis of genetic testing. Total thyroidectomy prior to the development of invasive cancer completely avoids an otherwise lethal malignancy. Timing of prophylactic surgery is based on models that utilise genotype-phenotype correlations, which have now been stratified into three risk groups based on the specific codon involved. MTC should be followed with postoperative serial serum calcitonin levels to survey for persistent or recurrent disease as indicated by detectable levels. The challenge however, if calcitonin levels are increased, is to find the source of its production. The first localisation technique recommended would be ultrasound of the neck, since there is a high frequency of local recurrence and cervical node metastasis, followed by a total body CT scan and bone scintigraphy.

Global DNA methylation profile in medullary thyroid cancer patients

2018 ◽  
Vol 105 (1) ◽  
pp. 110-114 ◽  
Author(s):  
Lucieli Ceolin ◽  
Ana Paula Palauro Goularte ◽  
Carla Vaz Ferreira ◽  
Mírian Romitti ◽  
Ana Luiza Maia
Keyword(s):  
Dna Methylation ◽  
Thyroid Cancer ◽  
Cancer Patients ◽  
Medullary Thyroid Cancer ◽  
Methylation Profile ◽  
Global Dna Methylation ◽  
Medullary Thyroid ◽  
Dna Methylation Profile
Sign in / Sign up

Export Citation Format

Share Document